Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Xavier

Urogynecology and Reconstructive Pelvic Surgery Arlington, TX Medical Doctor

NPI 1093854028 CMS profile 49783

5005 S Cooper St Ste 250, Ste 250, Arlington, TX 76017

Open in the dashboard

General payments

$282,218

753 records reported · program years 2019–2025

Research payments

$2,096

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$688,471 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Keith Xavier of Arlington, TX is reported in the CMS Open Payments database as having received $282,218 across 753 general payments and $2,096 in research payments paid to them. Separately, studies naming them as principal investigator received $688,471 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58,154 172
2024 General $19,621 86
2023 General $14,318 75
2022 General $62,827 153
2022 Research $2,096 2
2021 General $34,851 99
2020 General $36,551 74
2019 General $55,896 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Xavier
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Keith Xavier were reported at $58,154. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Keith Xavier Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $55,896 $799 $319–$2,013 $163
2020 $36,551 $384 $158–$1,360 $114
2021 $34,851 $641 $247–$2,515 $132
2022 $62,827 $843 $347–$2,794 $149
2023 $14,318 $819 $308–$2,302 $160
2024 $19,621 $882 $306–$2,459 $164
2025 $58,154 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $178,863 415 payments
  2. Medtronic USA, Inc. $43,401 101 payments
  3. Caldera Medical, Inc $36,536 15 payments
  4. Astellas Pharma US Inc $14,124 28 payments
  5. Boston Scientific Corporation $1,201 21 payments
  6. Teleflex LLC $1,195 14 payments
  7. Bluewind Medical $1,075 10 payments
  8. AbbVie, Inc. $862 42 payments
  9. Axonics Modulation Technologies, Inc. $686 10 payments
  10. NeoTract Inc. $568 8 payments
  11. Other $3,708 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $195,440 83 payments
  2. Consulting Fee $39,325 7 payments
  3. Food and Beverage $30,853 556 payments
  4. Travel and Lodging $16,264 100 payments
  5. Gift $132 5 payments
  6. Grant $114 1 payment
  7. Education $90 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $146,213 323 payments
  2. INTERSTIM Sacral Nerve Stimulation $42,155 90 payments
  3. Desara $36,536 15 payments
  4. ALTAVIVA $27,819 59 payments
  5. Vertessa $26,800 1 payment
  6. MYRBETRIQ $14,034 27 payments
  7. UROLIFT $965 13 payments
  8. REVI $755 6 payments
  9. INTERSTIM ICON $553 8 payments
  10. GEMTESA $548 10 payments
  11. Other $7,845 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,096 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,351

Median for Urology: 1,053

Drug cost

$176,872

Median for Urology: $101,464

Branded share of claims

35.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 107 $85,907
Myrbetriq Mirabegron Brand 73 $59,712
Mirabegron Er Mirabegron Brand 14 $8,999
Methenamine Hippurate Generic 92 $8,659
Estradiol Generic 67 $4,530
Tamsulosin Hcl Generic 179 $2,071
Solifenacin Succinate Generic 48 $2,037
Finasteride Generic 121 $1,484
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 71 $1,046
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 172 $523

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$351,676

Medicare's payments for the services billed

Medicare patients

665

Average age 77

Services billed

6,985

335 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 35%
Chronic kidney disease 34%
Ischemic heart disease 33%
Depression 25%
Atrial fibrillation 24%
Cancer 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $339
$339 107 —
ERLEADA
  • Janssen Biotech, Inc. $201
$201 — —
BOTOX
  • AbbVie, Inc. $177
$177 — —
AKEEGA
  • Janssen Biotech, Inc. $58
$58 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

755 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record